Why the study?
Is the ACE insertion/deletion (I/D) gene polymorphism associated with an increased risk of hematological malignancies?
Case-Control
Is the ACE insertion/deletion (I/D) gene polymorphism associated with an increased risk of hematological malignancies?
Effect estimate: 3.2 fold increased risk
Absolute Event Rate: 80.4% vs 55.9%
The presence of the ACE insertion allele (ID/II genotype) is associated with a 3.2-fold increased risk of hematological malignancies, suggesting a role for the local bone marrow renin-angiotensin system in leukemic hematopoiesis.
Local bone marrow renin-angiotensin system (RAS) is an autocrine-paracrine system affecting normal and neoplastic hematopoiesis. Angiotensin converting enzyme (ACE) converts angiotensinogen-I to its physiologically active peptide angiotensin-II, which stimulates proliferation and differentiation of hematopoietic stem cells through angiotensin II type 1 receptors. We investigated the ACE insertion/deletion (I/D) gene polymorphisms in patients with hematological malignancies including acute and chronic leukemia, myelodysplastic syndrome and multiple myeloma. Our results showed that 80.4% of the patients represented ID/II genotype, whereas it was 55.9% of the control group and 3.2 fold increased disease risk in the existence of insertion allele (ID/II). This is the first study demonstrating possible effects of ACE I/D gene polymorphism of the local bone marrow RAS components on leukemic hematopoiesis.
No takes yet. Share an insight, caveat, or question.
İbrahim Akalın (2011) conducted a case-control in Hematological malignancies. ACE insertion/deletion (I/D) gene polymorphisms (ID/II genotype) vs. Control group was evaluated on Presence of ID/II genotype (3.2 fold increased risk).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: